Tranquil™ to provide high-CBD, low-THC tincture oil for patients with intractable epilepsy
AUSTIN, Texas, Dec. 13, 2018 /PRNewswire/ — Surterra Wellness (Surterra), one of the fastest growing health and wellness companies in the United States, today announced the Texas launch of Tranquil™, a high-CBD, low-THC medical cannabis tincture for patients living with intractable epilepsy.
“We are thrilled to offer epilepsy patients in Texas a compelling new treatment option through the launch of Surterra’s first medical cannabis product in the state,” said Surterra Chief Executive Officer William “Beau” Wrigley, Jr. “Today’s launch represents the latest achievement in a transformative year for Surterra, as we continue to deliver on our strategy of building an industry-leading portfolio of brands and products trusted by consumers.”
Tranquil contains greater than 10% by weight of cannabidiol (CBD), up to 0.5% by weight of tetrahydrocannabinol (THC), and a targeted blend of naturally-derived terpenes selected for anticonvulsant properties. Studies have found medical cannabis to be an effective treatment option in reducing the number of seizures experienced by epilepsy patients.
“With growing evidence confirming medical cannabis as an effective treatment for epilepsy, Tranquil’s innovative combination of high-CBD, low-THC and targeted terpenes provides a safe and effective natural treatment option to help Texas patients control their seizures,” said Marcus Ruark, President of Surterra Wellness, Texas.
Surterra’s introduction of Tranquil is the latest step in the company’s strategy to provide high-quality, consistent medical cannabis to patients in Texas, where Surterra owns one of three licenses to grow, process and sell medical cannabis. Texas, which launched its medical cannabis market in early 2018, allows for approved dispensaries to produce medical cannabis for individuals suffering from intractable epilepsy.
The Texas launch of Tranquil comes just two days after Surterra announced its expansion into Nevada with the partnership with The Apothecary Shoppe, a premier vertically-integrated cannabis company based in Las Vegas. The partnership allows Surterra to offer its brands in a third market and to continue The Apothecary Shoppe’s commitment to providing safe, natural, high-quality cannabis-based products to a growing market in Nevada.
With operations in Florida, Texas and now Nevada, Surterra is one of the largest U.S. providers of medical, wellness and lifestyle cannabis products. The company operates 16 Surterra Wellness Centers and over 300,000 square feet of canopy throughout Florida and is under contract to expand to over 500,000 square feet of cultivation by mid-2019. Demonstrating the company’s rapid progression in an evolving wellness industry, Surterra expanded from 100 to over 550 employees in 2018 and anticipates continued aggressive expansion through organic growth as well as by entering new markets throughout 2019.
The Texas and Nevada announcements further build on Surterra’s progress in 2018, which has included:
- In November, business leader and entrepreneur William “Beau” Wrigley Jr., former CEO of the Wrigley Co., became the company’s CEO; and
- In September, Surterra reached a landmark global licensing deal with Jimmy Buffett’s Margaritaville team to create a new medical marijuana brand, Coral Reefer.
About Surterra Wellness
Founded in 2014, Surterra Wellness is one of the fastest growing health and wellness cannabis companies in the United States. With licenses in Florida, Texas and Nevada, Surterra brings a broad portfolio of high-quality brands to meet the needs of individuals who choose the natural medical relief, wellness enhancing or lifestyle enjoyment benefits of cannabis products. Surterra offers a wide variety of medical, health and wellness products in multiple delivery options including vaporizer pens, tinctures, topical creams, time released transdermal patches, and soon-to-be-launched softgels.
About Cannabis and Epilepsy
A growing body of studies and clinical trials confirms the benefits of medical cannabis in controlling epileptic seizures. In particular, treatments that incorporate cannabidiol (CBD) have shown promise in providing relief for individuals who have not responded to traditional therapies for seizure reduction. Earlier this year, the U.S. Food & Drug Administration (FDA) issued its first-ever approval of a cannabis-based medicine for patients suffering from two rare forms of epilepsy (Lennox-Gastautsyndrome and Dravet syndrome). The approval further validated the benefits of medical cannabis as a safe and effective natural treatment option for serious medical conditions and represented a significant step forward as medical cannabis continues to make a positive, meaningful impact on patient health and wellness.
Learn more: https://www.surterra.com/learn/medical-cannabis/epilepsy/
SOURCE Surterra Wellness
